Subthalamic nucleus influences spatial orientation in extrapersonal spaceWITT, Karsten; KOPPER, Florian; DEUSCHL, Günther et al.Movement disorders. 2006, Vol 21, Num 3, pp 354-361, issn 0885-3185, 8 p.Article

The impact of normal aging and Parkinson's disease on response preparation in task-switching behaviorWITT, Karsten; DANIELS, Christine; SCHMITT-ELIASSEN, Julia et al.Brain research. 2006, Vol 1114, pp 173-182, issn 0006-8993, 10 p.Article

Subthreshold Depression in Parkinson's DiseaseREIFF, Julia; SCHMIDT, Nele; RIEBE, Bastian et al.Movement disorders. 2011, Vol 26, Num 9, pp 1741-1744, issn 0885-3185, 4 p.Article

Patients with Parkinson's disease learn to control complex systems- : an indication for intact implicit cognitive skill learningWITT, Karsten; DANIELS, Christine; DANIEL, Victoria et al.Neuropsychologia. 2006, Vol 44, Num 12, pp 2445-2451, issn 0028-3932, 7 p.Article

Feedback-based versus observational classification learning in healthy aging and Parkinson's diseaseSCHMITT-ELIASSEN, Julia; FERSTL, Roman; WIESNER, Christian et al.Brain research. 2007, Vol 1142, pp 178-188, issn 0006-8993, 11 p.Article

Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's diseaseHERZOG, Jan; REIFF, Julia; KRACK, Paul et al.Movement disorders. 2003, Vol 18, Num 11, pp 1382-1384, issn 0885-3185, 3 p.Article

Influence of Subthalamic Deep Brain Stimulation Versus Levodopa on Motor Perseverations in Parkinson's DiseaseHERZOG, Jan; MÖLLER, Bettina; WITT, Karsten et al.Movement disorders. 2009, Vol 24, Num 8, pp 1206-1210, issn 0885-3185, 5 p.Article

Neuropsychological consequences of endarterectomy and endovascular angioplasty with stent placement for treatment of symptomatic carotid stenosis : A prospective randomised studyWITT, Karsten; BORSCH, Katharina; DANIELS, Christine et al.Journal of neurology. 2007, Vol 254, Num 11, pp 1524-1532, issn 0340-5354, 9 p.Article

Effects of smoking on the pharmacokinetics of erlotinibHAMILTON, Marta; WOLF, Julie L; RUSK, Jason et al.Clinical cancer research. 2006, Vol 12, Num 7, pp 2166-2171, issn 1078-0432, 6 p., 1Article

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjectsHAMILTON, Marta; WOLF, Julie L; DROLET, Daniel W et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 613-621, issn 0344-5704, 9 p.Article

Is Improvement in the Quality of Life After Subthalamic Nucleus Stimulation in Parkinson's Disease Predictable?DANIELS, Christine; KRACK, Paul; DANEK, Adrian et al.Movement disorders. 2011, Vol 26, Num 14, pp 2516-2521, issn 0885-3185, 6 p.Article

Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's diseaseWITT, Karsten; DANIELS, Christine; DANEK, Adrian et al.Journal of the neurological sciences. 2011, Vol 310, Num 1-2, pp 261-266, issn 0022-510X, 6 p.Article

Risk Factors for Executive Dysfunction After Subthalamic Nucleus Stimulation in Parkinson's DiseaseDANIELS, Christine; KRACK, Paul; DANEK, Adrian et al.Movement disorders. 2010, Vol 25, Num 11, pp 1583-1589, issn 0885-3185, 7 p.Article

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studiesWACKER, Bret; NAGRANI, Tina; WEINBERG, Jacqueline et al.Clinical cancer research. 2007, Vol 13, Num 13, pp 3913-3921, issn 1078-0432, 9 p.Article

Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared to finger movementsWENZELBURGER, Roland; KOPPER, Florian; KRACK, Paul et al.Movement disorders. 2003, Vol 18, Num 10, pp 1162-1169, issn 0885-3185, 8 p.Article

Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trialWITT, Karsten; GRANERT, Oliver; DANIELS, Christine et al.Brain. 2013, Vol 136, pp 2109-2119, issn 0006-8950, 11 p., 7Article

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionO'BRYANT, Cindy L; HALUSKA, Paul; BELANI, Chandra et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 3, pp 605-612, issn 0344-5704, 8 p.Article

Provocation of Parkinsonian tremorRAETHJEN, Jan; AUSTERMANN, Kristina; WITT, Karsten et al.Movement disorders. 2008, Vol 23, Num 7, pp 1019-1023, issn 0885-3185, 5 p.Article

Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2LILENBAUM, Rogerio; AXELROD, Rita; THOMAS, Sachdev et al.Journal of clinical oncology. 2008, Vol 26, Num 6, pp 863-869, issn 0732-183X, 7 p.Article

Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's diseaseWITT, Karsten; DANIELS, Christine; HERZOG, Jan et al.The Journal of neuropsychiatry and clinical neurosciences. 2006, Vol 18, Num 3, pp 397-401, issn 0895-0172, 5 p.Article

Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson diseaseWITT, Karsten; PULKOWSKI, Ulrich; HERZOG, Jan et al.Archives of neurology (Chicago). 2004, Vol 61, Num 5, pp 697-700, issn 0003-9942, 4 p.Article